Belenosbio
1 known investors
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
BiotechHealthtech
Founders & leadership
DM
Donnie McGrathCEO & Co-Founder
MD
Megan DowCOO & Co-Founder
TD
Tania DimitrovaCFO & Co-Founder
GR
Glenn RosenChief Translational Officer & Co-Founder